Please login to the form below

Not currently logged in
Email:
Password:

fasinumab

This page shows the latest fasinumab news and features for those working in and with pharma, biotech and healthcare.

Lilly, Pfizer say NGF drug works in back pain too

Lilly, Pfizer say NGF drug works in back pain too

Pfizer/Lilly’s tanezumab – along with Regeneron/Teva’s fasinumab which reported positive phase 3 results in osteoarthritis last year – are the only NGF-targeting drugs that remain in late-stage

Latest news

More from news
Approximately 4 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Deal Watch September 2016 Deal Watch September 2016

    4, 325. Regeneron / Teva. Licence. Fasinumab in P3 for osteoarthritis pain, upfront payment $250m [excludes rights to Japan, Korea and other Asian markets].

  • Deal Watch October 2015 Deal Watch October 2015

    Collaboration, option to license. 339. Regeneron Pharmaceuticals/ Mitsubishi Tanabe Pharma. Fasinumab (REGN475), nerve growth factor  mAb for musculoskeletal pain (p2b).

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

The importance of co-creation with patients
Overcoming the barriers...
Three billboards on the road to multichannel
Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics